|
|
9005 Westside Parkway
Alpharetta, GA 30009 USA
phone:678.746.1100
fax:678-746-1299
|
|
| Symbol |
INHX |
| Exchange |
NASDAQ |
| Founded |
1998 |
| Employees |
|
|
|
| www.inhibitex.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products to prevent serious infections |
|
| Management |
| Russell H. Plumb, M.B.A., President and Chief Executive Officer; Joseph M. Patti, M.S.P.H., Ph.D., Co-Founder, Chief Scientific Officer and Senior Vice President of Research and Development; Geoffrey Henson, PhD, Senior Vice President of Drug Development; Stan Chamberlain, Ph.D, Vice President of Chemistry; Jeff Hutchins, Ph.D., Vice President of PreClinical Development |
| |
|
|
|
|
|
|
|
| Keywords |
| herpes zoster, aureus, staphylococcal, humanized, monoclonal |
|
|
|
| Description |
|
Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying their expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
